Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Cowen & Co. Maintains Outperform on Caterpillar, Lowers Price Target to $225

Cowen & Co. Maintains Outperform on Caterpillar, Lowers Price Target to $225

Cowen & Co. analyst Matt Elkott maintains Caterpillar (NYSE:CAT) with a Outperform and lowers the price target from $255 to $225.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Cowen & Co. analyst Matt Elkott maintains Caterpillar (NYSE:CAT) with a Outperform and lowers the price target from $255 to $225.

Why ChargePoint’s Dip Is Your Ticket To Electric Profits: What 2 Analysts Think

By AJ Fabino

March 3, 11:03 AM

Shares of ChargePoint Holdings Inc (NYSE: CHPT) fell more than 11% in Friday’s premarket session after the company reported an earnings miss and issued guidance below consensus estimates.

CHPT

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $6,800 Today

By Benzinga Insights

January 31, 2:33 PM

Tyson Foods (NYSE:TSN) has outperformed the market over the past 20 years by 1.98% on an annualized basis…

TSN

Revelation Biosciences Q2 EPS $(0.12)

By Michael Horton

August 15, 5:31 PM

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.12) per share.

REVB

Analyst Ratings

Where Phathom Pharmaceuticals Stands With Analysts

By Benzinga Insights

April 5, 1:00 PM

Phathom Pharmaceuticals (NASDAQ:PHAT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

PHAT

Cowen & Co. Maintains Outperform on Caterpillar, Lowers Price Target to $225

Related Posts

Why ChargePoint’s Dip Is Your Ticket To Electric Profits: What 2 Analysts Think

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $6,800 Today

Revelation Biosciences Q2 EPS $(0.12)

Where Phathom Pharmaceuticals Stands With Analysts